Investigational New Drugs

, Volume 23, Issue 3, pp 253–256 | Cite as

Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma

  • Michael J. MillwardEmail author
  • Anthony Joshua
  • Rick Kefford
  • Steinar Aamdal
  • Damien Thomson
  • Peter Hersey
  • Guy Toner
  • Kevin Lynch


Purpose: To determine the activity and tolerability of SAM496A, an inhibitor of S-adenosylmethionine decarboxylase (SAMDC), in patients with metastatic melanoma who had not received prior chemotherapy. Selected patients were offered participation in two sub-studies examining early changes in tumor metabolism with FDG-PET and changes in tumor polyamine content.

Patients and methods: Fifteen patients with measurable metastatic melanoma, normal cardiac function, and no known CNS metastases were eligible and received SAM486A by 1-hour IV infusion daily for 5 days every 3 weeks. Response was assessed by SWOG criteria.

Results: No patient had a confirmed partial response. Fatigue/lethargy, myalgia and neutropenia were the main toxicities but no febrile neutropenia or grade 4 non-hematological toxicity occurred. Five patients had PET scans pre-treatment and on days 8–12 of cycle 1. No patient had reduction of tumor metabolism. Serial biopsy in one patient showed alterations in polyamines consistent with SAMDC inhibition.

Conclusions: Using the present dose and schedule of administration, SAM486A does not have significant therapeutic potential in patients with metastatic melanoma.

Key words

melanoma polyamines PET scanning 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chapman PB, Einhorn LH, Meyers M, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM: Phase III multicenter randomised trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17(9): 2745–2751, 1999PubMedGoogle Scholar
  2. 2.
    Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH: Phase III trial of dacarbazine versus dacarbazine with interferon α-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon α-2b and tamoxifen in patients with metastatic malignant melanoma. An Eastern Cooperative Group study. J Clin Oncol 16(5): 1743–1751, 1998PubMedGoogle Scholar
  3. 3.
    Eton O, Legha SS, Bedekian AY, Lee JJ, Buzaid AC, Hodges C, Ring SE, Papadopoulos NE, Plager C, East MJ, Zhan F, Benjamin RS: Sequential biochemotherapy versus chemotherapy for metastatic melanoma: Results from a Phase III randomised trial. J Clin Oncol 20(8): 2045–2052, 2002CrossRefPubMedGoogle Scholar
  4. 4.
    Warrell RP, Burchenal JH: Methylglyoxal bis(guanylhydrazone) (methyl-GAG): Current status and future prospects. J Clin Oncol 1: 52–65, 1983PubMedGoogle Scholar
  5. 5.
    Regenass U, Mett H, Stanek J, Mueller M, Kramer D, Porter CW: CGP48664, a new $S$-adenosylmethionine decarboxylase inhibitor with broad spectrum antiproliferative and antitumor activity. Cancer Res 54: 3210–3217, 1994PubMedGoogle Scholar
  6. 6.
    Gutman M, Beltran PJ, Fan D, Delworth MG, Singh RK, Wilson MR, Fidler IJ: Treatment of nude mice with 4-amidinoindan-1-one2’-amidinohydrazone, a new $S$-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastases of human melanoma cells. Melanoma Res 5: 147–154, 1995PubMedGoogle Scholar
  7. 7.
    Eskens FALM, Griem GA, van Zuilen C, Wolff I, Denis LJ, Planting AST, Muskiet FA, Wanders J, Barbet NC, Choi L, Capdeville R, Verweij J, Hanauske A-R, Bruntsch U: Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM486 (CGP48664) in patients with solid tumors. Clin Cancer Res 6: 1736–1743, 2000PubMedGoogle Scholar
  8. 8.
    Paridaens R, Uges DRA, Barbet N, Choi L, Seeghers M, van der Graaf WTA, Groen HJM, Dumwz H, van Buuren I, Muskiet F, Capdeville R, van Oosterom AT, de Vries EGE: A Phase I study of a new polyamine biosynthesis inhibitor, SAM486A, in cancer patients with solid tumors. Br J Cancer 83: 594–601, 2000CrossRefPubMedGoogle Scholar
  9. 9.
    Siu LL, Rowinsky EK, Hammond LA, Weiss GR, Hidalgo M, Clark GM, Moczygemba J, Choi L, Linnartz R, Barbet NC, Sklenar IT, Capdeville R, Gan G, Porter CW, Von Hoff DD, Eckhardt SG: A Phase I and pharmacodynamic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with advanced solid tumors. Clin Cancer Res 8: 2157–2166, 2002PubMedGoogle Scholar
  10. 10.
    Kramer DL, Mett H, Regenass U, Diegelman P, Porter CW: Stable amplification of the $S$-adenosylmethionine decarboxylase gene in Chinese hamster ovary cells. J Biol Chem 270: 2124–2132, 1995CrossRefPubMedGoogle Scholar
  11. 11.
    Green S, Weiss GR: Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs 10: 239–253, 1992CrossRefPubMedGoogle Scholar
  12. 12.
    Pless M, Belhadj K, Menssen HD, Kern W, Coiffier B, Wolf J, Herrmann R, Thiel E, Bootle D, Sklenar I, Muller C, Choi L, Porter C, Capdeville R, et al.: Clinical efficacy, tolerability, and safety of SAM486A, a novel polyamine biosynthesis inhibitor, in patients with refractory or relapsed non-Hodgkin’s lymphoma: Results from a Phase II study. Clin Cancer Res 10: 1299–1305, 2004PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Michael J. Millward
    • 1
    • 8
    Email author
  • Anthony Joshua
    • 1
  • Rick Kefford
    • 2
  • Steinar Aamdal
    • 3
  • Damien Thomson
    • 4
  • Peter Hersey
    • 5
  • Guy Toner
    • 6
  • Kevin Lynch
    • 7
  1. 1.Sydney Cancer Centre & Sydney Melanoma UnitRoyal Prince Alfred HospitalSydneyAustralia
  2. 2.Westmead Hospital & Sydney Melanoma UnitSydneyAustralia
  3. 3.The Norwegian Radium HospitalOsloNorway
  4. 4.Princess Alexandra HospitalBrisbaneAustralia
  5. 5.Royal Newcastle Hospital & Sydney Melanoma UnitNewcastleAustralia
  6. 6.Peter MacCallum Cancer InstituteMelbourneAustralia
  7. 7.Novartis Pharma Pty LtdSydneyAustralia
  8. 8.School of Medicine and PharmacologySir Charles Gairdner Hospital Unit M503PerthAustralia

Personalised recommendations